|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Somatic alterations of the DPC4 and Madr2 genes in colorectal cancers and relationship to metastasis.
|
11172591 |
2001 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Other members of the SMAD family are excellent candidates for JPS, especially SMAD2 (which, like SMAD4, is mutated somatically in colorectal cancers), SMAD3 (which causes colorectal cancer when "knocked out" in mice), SMAD5, and SMAD1.
|
10446110 |
1999 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data suggest that the carcinogenetic pathways of protruding and superficial depressed colorectal cancers are different, and that alterations of tumor suppressor gene(s) located on 18q21 other than Smad2, Smad4 and DCC might be associated with most superficial depressed colorectal cancers.
|
10665650 |
1999 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A similar invasive phenotype was obtained in cells expressing another inactivating mutation in Smad2 (Smad2.P445H) found in colorectal cancer.
|
10438456 |
1999 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
By the PCR-SSCP method using these primers, we screened genomic DNA sequences of colorectal cancers for mutations of the Smad2 gene.
|
9635866 |
1998 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The SMAD-2 gene may play a role as a candidate tumour-suppressor gene in a small fraction of colorectal cancers.
|
9820171 |
1998 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
RT-PCR sequencing analysis of the HL60 Smad5 remaining allele ruled out the functional inactivation of the gene analogous to that occurring in the Smad5 homologs DPC4 and Smad2 in cases of pancreatic and colorectal cancers.
|
9264367 |
1997 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
DPC4 and MADR2/JV18-1 are recently demonstrated to be altered in pancreatic and colorectal cancers, respectively.
|
9288786 |
1997 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings suggest that MADR2 is a tumor suppressor and that mutations acquired in colorectal carcinomas may function to disrupt TGFbeta signaling.
|
8752209 |
1996 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Loeys-Dietz Syndrome
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
CNC-, but not SHF-specific, deletion of Smad2 preserved aortic wall architecture and reduced aortic dilation in this mouse model of LDS.
|
30614814 |
2019 |
|
Loeys-Dietz Syndrome
|
0.330 |
Biomarker
|
disease |
BEFREE |
More recently, TGF-β ligands, TGFB2 and TGFB3, as well as intracellular downstream effectors of the TGF-β pathway, SMAD2 and SMAD3, were shown to be involved in LDS.
|
29392890 |
2018 |
|
Loeys-Dietz Syndrome
|
0.330 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
More recently, TGF-β ligands, TGFB2 and TGFB3, as well as intracellular downstream effectors of the TGF-β pathway, SMAD2 and SMAD3, were shown to be involved in LDS.
|
29392890 |
2018 |
|
Loeys-Dietz Syndrome
|
0.330 |
Biomarker
|
disease |
BEFREE |
Dysregulation of the TGF-ß pathway has been implicated in the pathogenesis of inherited disorders predisposing to thoracic aortic aneurysms syndromes (TAAS) including Marfan syndrome (MFS; FBN1) and Loeys-Dietz syndrome (LDS; TGFBR1, TGFBR2, TGFB2, TGFB3, SMAD2, SMAD3).
|
29350460 |
2018 |
|
Loeys-Dietz Syndrome
|
0.330 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
More recently, TGF-β ligands, TGFB2 and TGFB3, as well as intracellular downstream effectors of the TGF-β pathway, SMAD2 and SMAD3, were shown to be involved in LDS.
|
29392890 |
2018 |
|
Congenital heart disease
|
0.310 |
Biomarker
|
group |
GENOMICS_ENGLAND |
De novo mutations in histone-modifying genes in congenital heart disease.
|
23665959 |
2013 |
|
Congenital heart disease
|
0.310 |
AlteredExpression
|
group |
BEFREE |
From our results, we can conclude that maternal diabetes results in transient and localized alterations in CML, VEGF expression, and Smad2 phosphorylation overlapping with those regions of the developing heart that are most sensitive to diabetes-induced congenital heart disease.
|
19188426 |
2009 |
|
Geleophysic dysplasia
|
0.310 |
Biomarker
|
disease |
CTD_human |
In addition, we observed a significant increase in total and active TGF-beta in the culture medium as well as nuclear localization of phosphorylated SMAD2 in fibroblasts from individuals with geleophysic dysplasia.
|
18677313 |
2008 |
|
Geleophysic dysplasia
|
0.310 |
Biomarker
|
disease |
BEFREE |
In addition, we observed a significant increase in total and active TGF-beta in the culture medium as well as nuclear localization of phosphorylated SMAD2 in fibroblasts from individuals with geleophysic dysplasia.
|
18677313 |
2008 |
|
Liver carcinoma
|
0.300 |
PosttranslationalModification
|
disease |
BEFREE |
TGF-β1-induced phosphorylation of Smad2 and Akt was enhanced in RIG-I-deficient HCC spheres, knockdown of AKT gene expression abolishing the augmentation of TGF-β1-induced Smad2 phosphorylation.
|
31088527 |
2019 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
And we found that LY2109761 could inhibit cell proliferation by down-regulating the phosphorylation of Smad-2 as well as improved the therapeutic effect of TACE in a VX2 hepatocellular carcinoma model.
|
29416682 |
2018 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry (IHC), quantitative real-time PCR (qRT-PCR) or Western blot analysis was used to detect TRIM52, p21, matrix metalloproteinase 2 (MMP2), protein phosphatase, Mg<sup>2+</sup>/Mn<sup>2+</sup> dependent 1A (PPM1A), p-Smad2/3 and Smad2/3 levels in HCC tissues and cell lines.
|
29898761 |
2018 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In clinical HCC samples, GP73 positively correlated with TGF-β1/Smad2, which was upregulated in HCC.
|
29365054 |
2018 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Compared with the control, miR-340 was significantly lower in the serum of the HCC patients (p < 0.01). miR-340 was lower in HCC tissues than in adjacent; however, DcR3, TGF-β1 and Smad2 were higher (p < 0.01).
|
29311025 |
2018 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In analysis of correlation with tumor stage, both protein and mRNA expression of TGFβ1, Smad1, Smad2 and Smad4 in patients with stage III HCC were significantly lower than those with stage IV HCC (P < 0.001), while the protein and mRNA expression of Smad3 in patients with IV stage HCC was significantly higher in comparison to those with stage IV HCC (P < 0.001).
|
29799303 |
2018 |